ALZN on Nasdaq
Alzamend Neuro, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
-$8.8MNet income, fiscal 20262
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2026
-1196.4%Return on equity2
Financial statements
Every line of the income statement in the latest annual report, as filed.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Research and development | $3.6M | $1.4M |
| General and administrative | $5.1M | $3.1M |
| Total operating expenses | $8.8M | $4.5M |
| Loss from operations | -$8.8M | -$4.5M |
| Interest income | $1.1K | |
| Interest expense | -$6.6K | -$18.0K |
| Total other expense, net | -$5.5K | -$18.0K |
| NET LOSS | -$8.8M | -$4.5M |
| Dividends on preferred shares | -$117.0K | |
| Deemed dividend on warrant modification issued with preferred shares | -$473.2K | |
| NET LOSS AVAILABLE TO COMMON SHARES | -$8.8M | -$5.1M |
| Basic net loss per common share | -$2.63 | -$11.32 |
| Diluted net loss per common share | -$2.63 | -$11.32 |
| Basic weighted average common shares outstanding | 3.3M shares | 450.8K shares |
| Diluted weighted average common shares outstanding | 3.3M shares | 450.8K shares |
Every line of the balance sheet in the latest annual report, as filed.2
| Period ending | 2026-04-30 | 2026-01-31 | 2025-04-30 |
|---|---|---|---|
| Cash | $710.7K | $3.9M | |
| Prepaid expenses and other current assets | $1.1M | $228.7K | |
| TOTAL CURRENT ASSETS | $1.8M | $4.2M | |
| Property, plant and equipment, net | $314.9K | $425.6K | |
| TOTAL ASSETS | $2.1M | $4.6M | |
| Accounts payable and accrued liabilities | $1.3M | $634.8K | |
| TOTAL LIABILITIES, ALL CURRENT | $1.3M | $634.8K | |
| Common stock, $0.0001 par value: 300,000,000 shares authorized; 4,256,039 and 778,733 issued and outstanding as of April 30, 2026 and 2025, respectively | $425 | $78 | |
| Additional paid-in capital | $68.0M | $62.5M | |
| Accumulated deficit | -$67.3M | -$58.5M | |
| TOTAL STOCKHOLDERS EQUITY | $733.2K | $2.2M | $4.0M |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY | $2.1M | $4.6M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares issued | 4.3M shares | 778.7K shares | |
| Common stock, shares outstanding | 4.3M shares | 778.7K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.2
| Period ending | 2026-04-30 | 2025-04-30 |
|---|---|---|
| Net loss | -$8.8M | -$4.5M |
| Depreciation expense | $110.7K | $50.7K |
| Interest expense - debt discount | $9.3K | |
| Stock-based compensation to employees, directors and consultants | $707.5K | $325.1K |
| Prepaid expenses and other current assets | -$825.1K | -$149.5K |
| Accounts payable and accrued liabilities | $711.4K | -$2.3M |
| Net cash used in operating activities | -$8.1M | -$6.6M |
| Purchase of equipment | -$300.0K | |
| Net cash used in investing activities | -$300.0K | |
| Net proceeds from the issuance of common stock | $794.8K | $2.7M |
| Proceeds from stock option exercise | $600 | |
| Net proceeds from the issuance of preferred stock | $4.0M | $7.7M |
| Net cash provided by financing activities | $4.8M | $10.4M |
| Net (decrease) increase in cash | -$3.2M | $3.6M |
| Conversion of Series A convertible preferred stock to common stock | $7.1M | |
| Conversion of Series B convertible preferred stock to common stock | $2.1M | |
| Conversion of Series C convertible preferred stock to common stock | $5.8M | $239.7K |
| Fair value of warrants issued in connection with Series A convertible preferred stock | $1.6M | |
| Preferred stock dividends | $117.0K | |
| Conversion of note payable and accrued interest into Series A convertible preferred stock | $311.4K | |
| Exchange of Series A convertible preferred stock into Series C convertible preferred stock | $977.5K | |
| Fair value of warrants issued with preferred stock | $577.1K |
Recent filings
- Oct 9, 2026RW
- Sep 29, 20268-K
- Sep 10, 202610-Q
- Aug 31, 20264/A PRIMARY DOCUMENT
- Aug 31, 20264/A PRIMARY DOCUMENT
- Aug 31, 20264 PRIMARY DOCUMENT
- Aug 28, 2026PRE 14A
- Aug 21, 2026S-1
- Aug 20, 20263/A PRIMARY DOCUMENT
- Aug 20, 20264/A PRIMARY DOCUMENT
- Aug 4, 20265 PRIMARY DOCUMENT
- Aug 4, 20265 PRIMARY DOCUMENT
- Aug 4, 20265 PRIMARY DOCUMENT
- Aug 4, 20265 PRIMARY DOCUMENT
- Aug 4, 20265 PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11